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SATU KAJIAN TENTANG AKTIVITI ANTIHIPERTENSI EKSTRAK BUAH 
GARCINIA ATROVIRIDIS 
 
ABSTRAK 
 
Tumbuhan Garcinia atroviridis (GA) digunakan dalam perubatan tradisional untuk 
merawat sakit telinga, sakit tekak, batuk, kelumumur, sakit perut yang berkaitan 
dengan kehamilan dan juga penyakit darah tinggi. Dalam kajian ini, kesan 
antihipertensi berpandukan ekstraksi dan fraksi buah GA dijalankan untuk 
mengetahui komponen kimia yang paling aktif. Buah kepada pokok ini telah 
dikeringkan, dikisar halus dan diekstrak dengan menggunakan pelarut bersiri  iaitu 
petroleum eter, klorofom, metanol dan air. Ekstrak telah dikeringkan di bawah 
tekanan yang rendah dan kemudian dibeku-kering. Kesan kesemua ekstrak tersebut 
telah diuji ke atas gegelung aorta tikus. Petroleum eter ekstrak didapati sebagai 
ekstrak yang paling aktif dalam pengenduran fenilefrina (PE) pra-kontraksi pada 
gegelung aorta. Kemudian, ekstrak petroleum eter difraksi menggunakan pelarut n-
heksana dan diklorometana. Fraksi n-heksana (2 mg ml
-1
) adalah yang paling aktif 
dalam pengenduran gegelung aorta. Penyingkiran endotelium pada gegelung aorta 
tidak menghapuskan kesan pengenduran ekstrak petroleum eter GA dan dengan ini 
ianya dicadangkan kesan pengenduran ekstrak ini tidak bergantung kepada 
endotelium. Tikus hipertensi yang diberi rawatan oral pada dos 1 g kg
-1
 
mengurangkan tekanan sistolik darah dan kadar denyutan jantung secara signifikan 
dan ini menguatkan lagi kesan antihipertensi buah GA. Pada tikus yang dibius, 
suntikan ekstrak metanol dan air GA mengurangkan tekanan arteri mean (MAP), 
sistolik (SP), diastolik (DP) dan kadar denyutan jantung (HR) pada tikus normal 
xvi 
 
mengikut dos yang diberi. Suntikan ekstrak petroleum eter dan klorofom 
menyebabkan kenaikan MAP, SP, DP dan HR pada tikus normal. 
Mekanisma yang terlibat dalam pengurangan tekanan darah pada tikus dibius juga 
telah dikaji menggunakan fenilefrina (α-agonis), isoprenalina (β-agonis) dan 
asetilkolina (agonis kolinergik). Hasil kajian mendapati kenaikan MAP yang 
dirangsang oleh fenilefrin direncat secara signifikan oleh ekstrak air GA dan 
dicadangkan disebabkan oleh sekatan pada reseptor α-adrenergik. Kesan diuretik 
ekstrak metanol dan air juga dikaji. Tiada kesan signifikan pada pengeluaran air 
kencing dan pengambilan air, tetapi, kenaikan pengeluaran natrium yang signifikan 
telah didapati pada kumpulan tikus yang diberi ekstrak air GA. Oleh itu, kesan 
penurunan tekanan darah oleh ekstrak GA dicadangkan disebabkan oleh kesan 
vasodilasi dan aktiviti α-antagonis. Analisis kimia kualitatif pada ekstrak air GA 
menunjukkan kehadiran alkaloid, flavonoid, terpenoid, steroid, saponin dan glikosida 
kardiak.  
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AN EXPERIMENTAL STUDY ON ANTIHYPERTENSIVE ACTIVITY OF 
GARCINIA ATROVIRIDIS FRUIT EXTRACTS 
 
ABSTRACT 
 
Garcinia atroviridis (GA) plant has been used as a traditional medicine for treating 
earache, throat irritation, cough, dandruff and stomach disorders associated with 
pregnancy and hypertension. In the present study, the anti-hypertensive effects-
guided extraction and fractionation of GA fruit were carried out in an attempt to find 
the most active chemical component. The fruit of this plant was dried, ground and 
serially extracted with petroleum ether, chloroform, methanol and water. The extracts 
were dried under reduced pressure and later freeze-dried. The vasodilator effect of 
the extracts was examined on isolated rat aortic ring preparation. The petroleum ether 
extract was found to be the most potent in relaxing PE pre-contracted aortic rings. 
The petroleum ether extract was then fractionated with n-hexane and 
dichloromethane. The n-hexane fraction (2 mg ml
-1
) was found to be the most active 
in relaxing the aortic ring. Removal of the endothelium of the aortic ring did not 
abolish the relaxing property of petroleum ether extract which suggests that the 
relaxing effect of the extract is not endothelium dependent. Orally administered all of 
GA extracts (1 g kg
-1
)
 
significantly reduced the systolic blood pressure and heart rate 
of spontaneous hypertensive (SH) rats which support the antihypertensive effect of 
GA fruit. In anaesthetized rats, the intravenous administration of methanol and water 
extracts of GA dose-dependently reduced mean arterial pressure (MAP), systolic 
pressure (SP), diastolic pressure (DP) and heart rate (HR) of SD rats. The 
intravenous administration of petroleum ether and chloroform extracts caused an 
increase in MAP, SP, DP and HR in normotensive rats. The mechanism involved in 
xviii 
 
reducing blood pressure of anesthetized normotensive rats was examined using 
phenylephrine (an α-agonist), isoprenaline (a β-agonist) and acetylcholine (a 
cholinergic agonist). It was found that the increase in MAP induced by 
phenylephrine was significantly inhibited by water extract of GA. It suggests that the 
water extract of GA possess α-adrenergic receptor blocker activity. The diuretic 
effect of methanol and water extracts of GA was investigated. There was no 
significant increase in urine output and water intake but there was a significant 
increase in urinary sodium excretion in orally administered water extract of GA. 
Therefore, it can be suggested that the lowering of blood pressure effect of GA is due 
to it’s the vasodilator and α-antagonist activities. Qualitative chemical analysis 
suggests that the water extract of GA contained alkaloids, flavonoids, terpenoids, 
steroids, saponins and cardiac glycosides. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 The cardiovascular system 
The cardiovascular system composes of a set of tubes, blood vessels for the flowing 
of blood, and a pump which is the heart that produces the flow. In 1628, the 
experimental science of physiology begun when William Harvey presented that the 
entire system forms a circle in which the blood is continuously being pumped out of 
the heart via one set of vessels and returning via a different set. Blood is pumped 
through the pulmonary circulation, from the right half of the heart via the lungs and 
back to the left of the heart (Figure 1.1). The second circuit (systemic circulation) 
pumped the blood from the left half of the heart through all the tissues of the body 
except the lungs and then back to the right half of the heart. The vessels carrying 
blood away from the heart are called the arteries. The aorta is a single large artery 
whereby blood left the half left of the heart. From the aorta, branching arteries 
conduct blood to various organ and tissues and it is further divided into smaller 
branches which are called arterioles (Vander et al., 1970). 
The chambers of the heart normally contract in a coordinated manner, pumping 
blood efficiently by a route determined by the valves. The heart consists of three 
layers which are the epicardium, the myocardium and the endocardium. The 
autonomic nervous system of the heart is composed of dual innervation from the 
sympathetic and parasympathetic divisions. These nerves produce neural regulation 
of cardiac function via conduction tissue (Maximilian Buja, 2007). 
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Figure 1.1 : Systemic and pulmonary circulation of the heart (Adapted from 
McKinley and O’Louglin, 2007).
3 
 
1.1.1 Arteries and arterioles 
Blood is released with each heartbeat from the left ventricle into the aorta, where it 
flows quickly to the organs through large conduit arteries. Successive branching 
leads via muscular arteries to arterioles and capillaries, where gas and nutrient 
exchanges occur (Rang and Dale, 2007). Essential hypertension is related with 
increased peripheral vascular resistance to blood flow which is cause by reduction in 
the caliber and/or number of small arteries and arterioles which are the main 
resistance vessels (Intengan and Schiffrin, 2000; London and Guerin, 1999). The 
contractility of vascular smooth muscle cells in the walls of small arteries and 
arterioles determined the arterial blood pressure (Moosmang et al., 2003). The 
arterial system has two functions; first as a conduit function to supply blood flow to 
peripheral tissues and organs on the basis of a pressure gradient and second as 
cushioning function to transform the pulsatile flow produced by the intermittent 
ventricular ejection into a continuous flow of blood in the periphery (Safar et al., 
2003; London and Guerin, 1999).  
The key cause of increased peripheral resistance is a decrease in lumen diameter 
(Intengan and Schiffrin, 2000). The vascular alterations that are involved in the 
decreased lumen size may be influenced by several distally located structural, 
mechanical and functional factors. These include eutrophic and hypertrophic 
remodeling of arterial and arteriolar vessels. In eutrophic remodeling, the outer 
diameter and the lumen are decreased and the cross-sectional area of the media is 
unaltered, which produce a greater media-lumen ratio. This type of remodeling is 
usually found in mild, essential hypertensive patients. Meanwhile hypertrophic 
remodeling includes a thickening of the media that encroaches on the lumen which 
narrowed it and therefore increased the media-lumen ratio and medial cross-sectional 
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area (Intengan and Schiffin, 2000). This type of remodeling is found in renovascular 
hypertension patients.  Moreover, changes of the microenvironment (especially 
sodium and other cations), reduced endothelium-mediated vasodilation and 
genetically mediated modifications of vasomotor tone, resulting from smooth muscle 
or endothelial cells are also the factors that decrease arterial cross-sectional area 
(Safar et al., 2003). 
 
1.1.1.1 Anatomy of the arteries 
There are three layers in the arteries (Figure 1.2) : 
i) Tunica intima or interna is the inner most layer of the artery wall, and has 
intimate contact with the blood. It is composed of an endothelium and a 
subendothelial connective tissue separated from a circumferentially-
arranged smooth muscle cells called the internal elastic lamina. 
 
ii) Tunica media which is the middle layer of the vessel is the thickest layer 
in arteries. It is a circularly arranged elastic fiber, connective tissue and 
polysaccharide substances. Sympathetic innervation causes the smooth 
muscle to contract while relaxation of the fibers causes vasodilation.  
  
iii) Last but not least is tunica adventitia or externa, the outermost. It is fully 
made of loosely woven collagen, connective tissue fibrils and sympathetic 
nerves (McKingley and O’Loughlin, 2007). 
5 
 
 
Figure 1.2 : The layers of the blood vessel include intima, media and adventitia 
(Adapted from Seeley, 2008). 
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1.2 The vascular endothelium  
In earlier days it had been thought until 1981 that the vascular endothelium acts as a 
passive barrier between plasma and extracellular fluid. Nowadays, new discovery has 
found out that it is also a source of numerous potent mediators such as prostanoids, 
nitric oxide, peptides and endothelium-derived hyperpolarising factor(s) (EDHF(s)) 
(Rang and Dale, 2007) which regulate the vascular tone. Vascular endothelium lines 
the circulatory system and is comprised of a monolayer of endothelial cells. There 
are three types of endothelial cells based on their intercellular junctions which are 
continuous, fenestrated or discontinuous and they are very adaptable to the specific 
requirements of an individual organ (Pasyk and Jakobczak, 2004). The phenotype 
differs between species, different organs and also in a specific organ itself. For 
example, in the kidney, the endothelial cells are fenestrated in peritubular capillaries, 
discontinuous endothelium in glomerullar capillaries and continuos in other parts 
(Risau, 1995).  The other important role of endothelium of the cardiovascular system 
includes the synthesis and secretion of various molecules, haemostasis and 
coagulation, inflammatory responses, vasculogenesis and angiogenesis (Pries and 
Kuebler, 2006).   
Furchgott and Zawadzki, (1980) discovered an endothelium-derived relaxing factor 
in a study on the ability of acetylcholine to elicit relaxation of isolated strips of rabbit 
aorta which was entirely dependent on the presence of the endothelium, which was 
later  identified as nitric oxide (NO) (Palmer et al., 1987).  It was found out that the 
endothelial NO was synthesized by NOS from L-arginine, a semi-essential amino 
acid through an NG hydroxy-L-arginine intermediate yielding L-citrulline (Palmer et 
al., 1988). Nitric oxide produced by the vascular endothelium is a major regulator of 
vascular homeostasis and if the vascular function is impaired, it can lead to the 
7 
 
development of a number of clinical conditions (Moncada and Higgs, 2006). For 
example, changes in endothelial function is the first step towards the development of 
atherosclerosis, a disorder of large and medium arteries and contribute to their 
perpetuation and to the clinical manifestations of vascular diseases (Higashi et al., 
2009; Sima et al., 2009). Moreover, the production of NO is also due to the shear 
stress produced by the flowing blood and pulsatile stretch of the vascular wall 
(Fleming and Busse, 2003). 
NO is a highly reactive signaling molecule that is made in a wide variety of cells, 
mostly neurons, skeletal muscle, endothelial cells and certain immune system cells 
and regulates physiologic and pathophysiologic processes including cardiovascular, 
inflammation, immune and neurol functions (Paige and Jaffrey, 2007).  In these cells, 
NO is synthesized by NO synthase (NOS) isoenzymes which consist of two 
constitutive and one inducible isoform, each named for the initial cell type which it 
was isolated and encoded by a separate gene. NO which are present in endothelial 
cell are call endothelial NOS (eNOS) and neuronal NOS (nNOS) for NO present in 
neurons, both are constitutive isoform. The inducible isoform (iNOS) is present in 
macrophages and smooth muscle cells as a vital inflammatory mediator (Spieker et 
al., 2006).  
A study (Huang et al., 1995) has discovered the role of eNOS in vascular function 
whereby they disrupted the eNOS gene in mice. Their result showed that the eNOS 
mutant mice are hypertensive due to the lack of vascular response to acetylcholine. 
Other than that, a similar study done by Shesely et al., (1996 ) discovered similar 
result and they also observed reduction in the heart rates of the eNOS mutant mice (-
/-) significantly compared to +/+ and +/- mice. In 1998, Miyamoto et al.,  have 
investigated the molecular involvement of the eNOS gene in essential hypertension 
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and they found that there was a significant association of the Glu298 Asp 
polymorphism in the eNOS gene with essential hypertension in Japanese patients. 
All these studies concluded that eNOS is important for the regulation and 
maintenance of normal blood pressure. Furthermore, other studies discovered that 
eNOS -/- mice developed bicuspid aortic valve (Lee et al., 2000), heart failure and 
congenital septal defects (Feng et al., 2002) and major defects in lung morphogenesis 
(Han et al., 2004). 
 
1.3 Autonomic nervous system  
The motor portion of the nervous system consists of two major subdivisions: 
autonomic and somatic. The autonomic nervous system activities are under direct 
unconscious control or independent. The two major divisions of autonomic nervous 
system are sympathetic nervous system (SNS) and parasympathetic nervous system. 
Meanwhile somatic division is mainly concerned with consciously controlled 
functions, for example respiration, posture and movement.  
The increase of SNS activity is the primary cause of hypertension in humans and 
animal models (Wys, 1993). There are many studies that described the correlation 
between sympathetic activation and essential hypertension (DiBona, 2004). The 
abnormal renal excretory function is vital for the initiation and development of 
primary hypertension. The kidneys respond to changes in arterial pressure by 
changing the urinary water and sodium excretion. This happen through pressure 
natriuresis, the homeostasis of renal body fluid feedback mechanisms couples the 
long-term regulation of arterial pressure to extracellular volume. In normal 
regulation, an increase in arterial blood pressure will result in an increased in urinary 
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sodium and water excretion and thus blood volume is reduced and the blood pressure 
is returned to normal. Based on computer modeling studies, a sustained increase in 
arterial pressure will only happen if there is a chronic decrease in renal excretory 
function (DiBona, 2004).  
Moreover, nitric oxide (NO) deficiency may increase the SNS contribution towards 
some forms of hypertension (Wyss, 1993). For instance, in a study of L-NAME, (a 
NO synthesis inhibitor) treated rats with glucose infusion produced hypertension 
compared to responses to glucose and L-NAME alone that is not affected by 
combined α- and β-adrenoceptor blockade. The inhibition of NO by L-NAME 
increases the hypertensive effects and tachycardiac responses. These results suggests 
that NO may protect against hypertension during chronic glucose infusion through 
suppression of sympathetic activity (Claxton and Brands, 2003).  
There are also other factors that contribute to SNS activation which result in resistant 
hypertension such as obesity, obstructive sleep apnea and excess of aldosterone 
(Tsioufis et al., 2011). Resistant hypertension is uncontrolled blood pressure despite 
treatment with three antihypertensive agents. 
The role of SNS in the pathophysiology of hypertension and its complications means 
that the regulation of sympathetic activity should be a vital target of antihypertensive 
treatment. In addition, further investigation on mechanisms that leads to SNS 
activation is also very helpful in understanding and managing hypertension.  
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1.3.1 Adrenergic receptors 
The adrenergic receptors play an important role in regulating sympathetic nervous 
system activity and also as a site of action for many therapeutics agents. They are 
members of the G-protein coupled receptor superfamily (GPCR). α and β are the two 
families of receptors that were initially identified based on their responses to the 
adrenergic agonists epinephrine, norepinephrine and isoproterenol. The use of 
specific blocking drugs and the cloning of genes has revealed the molecular identities 
of a number of receptor subtypes. 
 
1.3.1.1 α-adrenergic receptors 
The α-adrenoceptors show a weak response to the synthetic agonist isoproterenol, but 
they are responsive to the naturally occurring catecholamines, epinephrine (EPI) and 
norepinephrine (NE). Both EPI and NE produce different effects. EPI relax smooth 
muscle and is only produced in the adrenal medulla while NE does not relax smooth 
muscle. NE acts as a neurotransmitter in the central nervous system and in the 
sympathetic nervous system at postganglionic neuro effector junctions (Insel, 1996). 
The α-adrenoceptors are further classified into two subgroups, α1 and α2 based on 
their affinities for α agonists and blocking drugs. α1 receptors are located on smooth 
muscle membrane of arteries, veins and sphincters of the urinary and gastrointestinal 
tract and involve in constriction of smooth muscle. The mechanism of action to 
activate the α-receptors is via G protein activation of phospholipase C that leads to 
the production of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from 
phosphatidylinositol. IP3 promote the release of Ca2+ from the endoplasmic reticulum 
into the cytosol and DAG turns on other proteins within the cell.  
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α2 receptors are present in presynaptic nerve endings. They are stimulated by EPI and 
NE to activate a negative feedback mechanism that reduces and modulates the 
release of additional NE. The effects of binding at α2 receptors are mediated by 
inhibition of adenylyl cyclase and a fall in the levels of intracellular cAMP. The α-
receptors are further categorized into α1A-, α1B-, α1D-, α2A-, α2B-, and α2C-. This 
classification is required for understanding the selectivity of some drugs (Harvey, 
2012; Hitner and Nagle, 2012).   
 
1.3.1.2 β-adrenergic receptors 
Initially, there were at least two subtypes of β-receptors, designated as β1 and β2. β1 
receptors have approximately equal affinity for EPI and NE, while β2 receptors have 
higher affinity for EPI than for NE. β3 was identified subsequently and was found in 
cardiac tissue and was reportedly to induce negative inotropic effect (Gauthier et al., 
1996). The β-adrenergic signaling pathway plays an important role in stimulation of 
the heart (β1) and bronchodilation (β2). Stimulation of β-adrenergic receptors 
increases heart rate, force of cardiac contraction, rate of cardiac relaxation and 
automaticity. These effects happen when this receptor is activated by adrenergic 
agonists or sympathetic neuronal stimulation (Post et al., 1999).  
The mechanism of action of β-adrenergic involves the stimulation of adenylyl 
cyclase by stimulatory G protein which increases the levels of cAMP and then, the 
phosphorylation of proteins through cAMP dependent protein kinase. The examples 
of these proteins are phospholamban, calcium channels and contractile proteins 
which after phosphorylation results in a functional response.  
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Isoproterenol is one example of drug that produces both β1 and β2 effects. This drug 
causes overstimulation of the heart along with bronchodilator effect. Because of this, 
researchers have investigated and discovered β drugs that would only stimulate β2 
receptors without causing excessive stimulation of β1 receptors in the heart. This is 
important for the treatment of bronchodilator. This is one example that shows the 
importance in knowing the function of receptor subtypes. 
 
1.4 Adrenergic antagonists 
The adrenergic antagonists (blockers or sympatholytic agents) bind to adrenoceptors 
but do not trigger the usual receptor-mediated intracellular effects. These drugs act 
by either reversibly or irreversibly attaching to the receptors, therefore preventing its 
activation by endogenous catecholamines. The antagonists are categorized according 
to their affinities for α and β receptors in the peripheral nervous system. Many 
adrenergic antagonists have important functions in clinical medicine, mainly to treat 
cardiovascular diseases (Harvey, 2012). 
 
1.4.1 α-adrenergic antagonist 
Drugs that block α-adrenoceptors significantly affect blood pressure. Since arteriolar 
and venous tone are determined by α-receptors on vascular smooth muscle, blockade 
of these receptors reduces the sympathetic tone of the blood vessels, leads to 
decrease peripheral vascular resistance which results in lower blood pressure. This 
also promotes a reflex tachycardia and postural hypotension (Bai, 2008; Katzung, 
2007). 
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Some examples of α-antagonists are phentolamine, prazosin, doxazosin, terazosin 
and tamsulosin. Phentolamine has been used in the treatment of pheochromocytoma 
and male erectile dysfunction. Prazosin, doxazosin and terazosin are beneficial in the 
treatment of hypertension. These drugs are selective competitive blockers of                 
α1-receptors. Meanwhile, tamsulosin are useful for the treatment of benign prostatic 
hypertrophy (Katzung, 2007). 
  
1.4.2 β-adrenergic antagonist 
All the clinically available β-blockers are competitive antagonists. Non-selective β-
blockers act at both β1- and β2-receptors, whereas cardioselective β-antagonists block    
β1-receptors. β-blocking drugs lower blood pressure in hypertensive patients but do 
not induced hypotension in normal patients. This is because the α-adrenoceptors 
remain functional which means the normal sympathetic control of the vasculature is 
maintained. β-receptor antagonists are primarily important in the treatment of angina, 
chronic heart failure and myocardial infarction (Harvey, 2012).  
One example of β-blocker is propranolol. This drug blocks the action of 
isoproterenol on the cardiovascular system. Hence, in the presence of propranolol, 
isoproterenol does not exert its effects which are increased heart rate or reductions in 
mean arterial pressure and diastolic pressure. Other examples of other β-blocker 
drugs are nadolol, timolol, pindolol and sotalol (Katzung, 2007). 
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1.5 Cholinergic receptors 
The cholinergic drugs act on receptors that are activated by acetylcholine (ACh). 
These drugs act by either stimulating or blocking receptors of the parasympathetic 
(cholinergic) nervous system. Neurotransmission in cholinergic neurons include six 
sequential steps which are synthesis, storage, release, binding of ACh to a receptor, 
degradation of the neurotransmitter in the synaptic cleft and recycling of choline and 
acetate. The synthesis of ACh involves choline transportation from the extracellular 
fluid into the cytoplasm. Choline acetyltransferase catalyzes the reaction of choline 
with acetyl coenzyme A (CoA) to form ACh in the cytosol. Acetyl CoA is derived 
from the mitochondria and is develop by the pyruvate oxidation and fatty acid 
oxidation. ACh is then stored into presynaptic vesicles by an active transport process 
coupled to the efflux of protons. Here, ACh is protected from degradation in the 
vesicle. The release of ACh happens when an action potential propagated by voltage-
sensitive sodium channels arrives at a nerve ending, causing an increase in the 
concentration of intracellular calcium. Then, ACh binds to postsynaptic cholinergic 
receptors which are classified into two; muscarinic and nicotinic. Afterwards, ACh is 
hydrolyzed by acetylcholinesterase in the synaptic cleft. Last but not least, choline is 
taken up by the neuron, acetylated into ACh and stored. These processes will be 
repeated after activation of subsequent action potential (Harvey, 2012). 
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Figure 1.3: Synthesis and release of acetylcholine from the cholinergic neuron.  
(Adapted from Harvey, 2012). 
 
 
1.5.1 Muscarinic receptors  
Muscarinic receptors belong to the class of G protein-coupled receptors. Five 
subclasses of muscarinic receptors have been identified: M1, M2, M3, M4 and M5. 
Nevertheless only M1, M2 and M3 have been functionally characterized. These 
receptors are located on ganglia of the peripheral nervous system and on the 
autonomic effector organs, for example the heart, smooth muscle, brain and exocrine 
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glands. M1-receptors are also found on gastric parietal cells, M2-receptors on cardiac 
cells and smooth muscle while M3 receptors on the bladder, exocrine glands and 
smooth muscle.  
The mechanism of action of M1- and M3-receptors involves the interaction with G 
protein which then activates phospholipase C. This result to the hydrolysis of 
phosphatidylinositol-(4,5)-bisphosphate to produce diacylglycerol (DAG) and 
inositol (1,4,5)-trisphosphate. Inositol (1,4,5)-trisphosphate causes an increase in 
intracellular Ca2+ while DAG activates protein kinase C. Ca2+ stimulates or inhibits 
enzymes or produce hyperpolarization, secretion or contraction while protein kinase 
C phosphorylates many proteins within the cell. This is the opposite to the M2-
mechanism of action which inhibits adenylyl cyclase and increase K+ conductance. 
The heart responds with a decrease in rate and force of contraction (Harvey, 2012). 
 
1.5.2 Nicotinic receptors    
Nicotinic receptors are found in the CNS, adrenal medulla, autonomic ganglia and 
the neuromuscular junction. These receptors recognize nicotine with only a limited 
affinity for muscarine. Nicotinic receptors belong to the superfamily of receptor-
gated ion channels and are composed of five subunits (Hosey, 1992). Two types of 
nicotinic receptors are identified: nicotinic-nerve (Nn) which is found at both the 
parasympathetic and sympathetic ganglia and nicotinic-muscle (Nm) which is 
located on cell membranes of skeletal muscle (Hitner and Nagle, 2012).  
The binding of two ACh molecules produce a conformational change that permits the 
entry of sodium ions, causing the depolarization of the effector cell. Low 
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concentration of nicotine stimulates the receptor while higher concentration blocks 
the receptor (Harvey, 2012). 
 
1.6 Blood pressure (BP) classification 
Blood pressure is a result of the factors that modulate cardiac output (CO) and 
peripheral resistance (PR). The formula for BP is  
BP = CO x PR 
Cardiac output is the amount of blood that is pumped out of the heart per minute. 
Peripheral resistance is the resistance that the arterioles have against the flow of 
blood. The increasing of these factors, heart rate, stroke volume or peripheral 
resistance will increase blood pressure and stimulation of the sympathetic nervous 
system will increase all the three factors. There are many factors that contribute to 
high blood pressure which include weight problem, high intake of sodium, smoking, 
lack of exercise and stress. Although these factors may not be the primary cause, 
controlling of these factors may result in modest decreases in BP (Hitner and Nagle, 
2012). 
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Table 1.1: Blood pressure classification. For classification of normal blood pressure, 
the requirements for both systolic and diastolic pressure must be met; for the 
remaining categories, either the systolic or the diastolic requirement must be met 
(Williams et al., 2009). 
Classification Systolic Diastolic 
 mmHg 
Normal <120 <80 
Prehypertension 120-139 80-89 
Stage 1 hypertension 140-159 90-99 
Stage 11 hypertension ≥160 ≥100 
 
 
 
 
Figure 1.4: Anatomic sites of blood pressure control (Adapted from Katzung, 2007). 
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1.7 Hypertension 
The most common cardiovascular disease is hypertension. Arterial blood pressure is 
an important indicator of a person’s state of health. If a person has low blood 
pressure, it is a medical emergency while blood pressure elevation directly indicates 
the risks of damage to kidney, heart and brain (Perloff et al., 1993). Mild 
hypertension (blood pressure 140/90 mmHg) also increases the risk of eventual end 
organ damage (Katzung, 2007). The gold standard for measurement of arterial 
pressure is with a catheter through direct intra-arterial measurement. However, as 
this technique is not practical for repeated measurements and large scale public 
health screening, the indirect method of measurement is commonly used. This 
technique required the use of sphygmanometer to measure the pressure that collapse 
the artery in the upper arm or leg (an occluding cuff, stethoscope and manometer).  
The cuff is inflated to a level above arterial pressure (as showed by obliteration of the 
pulse). As the cuff is gradually deflated, the pressure is noted through a series of 
sounds (Williams et al., 2009). The direct method measures pressure and the indirect 
method is more indicative of flow, therefore the results will be similar. The indirect 
method is generally less reproducible and less accurate (Perloff et al., 1993). 
However, it is claimed to be sufficiently accurate because it is practical, simple, cost 
effective and non-invasive.  
 
1.8 Synthetic drugs for the treatment of hypertension 
All antihypertensive agents act at one or more of the four anatomic control sites 
which are arterioles, venules, heart and kidneys and their effects are produced by 
interfering with normal mechanisms of blood pressure regulation (Katzung, 2007). 
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The classifications of these agents according to the principal regulatory site or 
mechanism on which they act include the following: 
i) Diuretics: Lower blood pressure by reducing blood volume through 
urinary excretion of water and electrolytes. Electrolytes are ion such as 
sodium (Na+), calcium (Ca++), chloride (Cl-) and potassium (K+). There 
are different diuretics drugs with different mechanisms. Below are the 
examples of the drugs and how they act: 
a) Thiazide diuretics: For examples, hydrochlorothiazide and 
chlorthalidone. These drugs lower blood pressure by increasing 
sodium and water excretion. This results in a decrease in extracellular 
volume which leads to decrease in cardiac output and renal blood 
flow.  
b) Loop diuretics: For examples, furosemide, bumetanide and torsemide. 
Loop diuretics cause decreased renal vascular resistance and increased 
renal blood flow. These drugs decrease blood potassium levels; act by 
inhibiting sodium and chloride reabsorption in the loop of Henle and 
distal tubule. This type of drug is the most efficacious of the diuretic 
drugs.   
c) Potassium-sparing diuretics: For examples, amiloride, eplerenone, 
spironolactone and triamterene. These drugs act in the collecting 
tubule to inhibit Na+ reabsorption and K+ excretion. 
 
ii) β-adrenoceptor-blocking agents: β-blockers acts primarily by decreasing 
cardiac output. They may also decrease sympathetic outflow from the 
central nervous system and inhibit the release of renin from the kidneys, 
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therefore decreasing the formation of angiotensin II and the excretion of 
aldosterone. They are divided into these classes: 
a) Drug which acts at both β1 and β2 receptors, for example, 
propranolol. 
b) Selective blockers of β1 receptors such as metoprolol, atenolol and 
nebivolol. 
 
iii) Angiotensin Converting Enzyme (ACE) inhibitors: lower blood pressure 
by decreasing peripheral vascular resistance without increasing cardiac 
output, rate or contractility. These drugs block or decrease the production 
or action of angiotensin II from angiotensin I via angiotensin-converting 
enzyme. Angiotensin II is one of the most potent natural vasoconstrictors 
known. By reducing angiotensin II levels, the secretion of aldosterone, a 
hormone from the adrenal gland that increases sodium reabsorption in the 
kidney, is also decreased. The increase in sodium reabsorption causes the 
body to retain water that raises blood volume and increases blood 
pressure. The decreasing blood pressure by blocking the effect of 
angiotensin II is through two mechanisms: dilating arteries and decreasing 
blood volume. 
 
iv) Angiotensin II-receptor blockers (ARBs): These drugs are alternatives to 
the ACE inhibitors. For examples, candesartan, eprosartan, irbesartan, 
losartan, valsartan etc. These drugs act by blocking the AT1 receptors and 
thus decreasing the activation of AT1 receptors by angiotensin II. Their 
effects are similar to ACE inhibitors in which they block aldosterone 
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secretion, hence lowering blood pressure and decreasing salt and water 
retention.  
 
v) Calcium-channel blockers: Calcium-channel antagonists block the inward 
movement of calcium by binding to L-type calcium channels in the heart 
and in smooth muscle of the coronary and peripheral arterial vasculature. 
This results in relaxation of smooth muscle, dilating arterioles. These 
blockers are categorized into three chemical classes, each with different 
pharmacokinetic properties and clinical purpose: 
 
a) Diphenylalkylamines: For example, verapamil. This drug exerted its 
effects on both cardiac and vascular smooth muscle cells. Hence, 
heart rate, contractility and blood pressure decrease. 
b) Benzothiazepines: For example, diltiazem. The effects is similar like 
verapamil except it has less pronounced negative inotropic effect on 
the heart compared to that of verapamil. 
c) Dihydropyridines: These include nifedipine, amlodipine, felodipine, 
isradipine, nicardipine and nisoldipine. These drugs have much higher 
affinity for vascular calcium channels than for calcium channels in the 
heart. These drugs functions mainly as arteriolar vasodilator, thus 
decreasing blood pressure.    
 
vi) α-adrenoceptor-blocking agents: For examples, prazosin, doxazosin and 
terazosin. These three drugs are selective α1-blocker. They act by 
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decreasing peripheral vascular resistance and lower arterial blood 
pressure via arterial and venous smooth muscle relaxation. 
 
vii)  β-adrenoceptor blocking agents: For examples, propranolol, metoprolol, 
atenolol, nebivolol. These drugs reduce blood pressure mainly by 
decreasing cardiac output. They might also decrease sympathetic outflow 
from the central nervous system (CNS) and inhibit the release of renin 
from the kidneys, hence decreasing the formation of angiotensin II and 
the secretion of aldosterone.  
 
 
viii) Centrally acting adrenergic drugs: Some examples of these drugs are 
clonidine, guanabenz, guanfacine and methyldopa. The mechanism of 
action involve the stimulation of inhibitory α2 receptors in the vasomotor 
center of the medulla oblongata which results in decrease of sympathetic 
stimulation to the heart, kidneys and blood vessels. For methyldopa, this 
α2 agonist forms α-methylnorepinephrine (false transmitter) to diminish 
adrenergic outflow from the CNS.  
 
ix) Vasodilators: Hydralazine and minoxidil are two examples of vasodilators 
drugs. Hydralazine causes direct vasodilation which act on arteries and 
arterioles. Meanwhile minoxidil dilates arterioles but not venules (Harvey 
et al., 2012; Holland and Adams, 2007). 
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1.9 The use of plant/herbal medicines in cardiovascular diseases 
 
The use of medicinal plants in treating, preventing or alleviating diseases has been of 
importance lately. Herbal or medicinal plants have been investigated extensively and 
it has been found that some of them have therapeutic effect including in 
cardiovascular diseases. Usually, these are folkloric medicines that have been used 
for generations. New technology in research has successfully proven their 
effectiveness and identified the compound(s) which exert its effects. Plants comprise 
of complex mixtures of metabolites and the products come in different form such as 
liquid, semi-solid or dry powder for internal or external use. Different methods of 
plant extractions are employed to obtain the therapeutically desired portions using 
specific solvent. These include maceration, infusion, hot continuous extraction 
(Soxhlet), decoction, super-critical fluid extraction, microwave-assisted extraction 
and hydrodistillation techniques (Tiwari et al., 2011). 
One example of medicinal plant that has been proven to have cardiovascular effects 
is aqueous extract of ginger which was reported to possess hypotensive, vasodilator, 
cardio suppressant and stimulant effects (Ghayur et al., 2005). Garlic (Allium 
sativum) also is widely known for its cardiovascular effects. A study by Matsuura, 
(2001) discovered that the saponins fractions from garlic lowered total plasma and 
low-density lipoprotein (LDL) cholesterol in a hypercholestrolemic animal model. 
Moreover, garlic extract has also been shown to relax endothelium dependent and 
independent pulmonary arteries and to inhibit endothelin-1 induced contraction 
(Kim-Park and Ku, 2000). The effect of garlic juice on reducing heart rate has also 
been reported. However at higher dosages, undesirable effect was obtained (Yadav 
and Verma, 2004). Water extract of garlic containing glutamylpeptides has the ability 
to inhibit angiotensin-converting enzyme (ACE) in-vitro which indicates that this 
